Enrolment complete and positive safety in Progenza trial
Filed with ASX · · 2 pages · English
Story so far
Earlier from Cambium Bio
- Response to 7.30 media commentary
- Appendix 4D and Half Yearly Report
- Positive safety of first cohort in Progenza stem cell trial
- Patent granted for cancer vaccine technology
Later from Cambium Bio
- ARC grant to progress stem cell research for chronic pain
- European patent to grant on stem cell secretions for acne
- Appendix 4E and Annual Report 2016
- Regeneus receives R&D tax incentive refund of $2.7m
- Japan Update
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio